These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31403661)

  • 1. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.
    Cantó E; Barro C; Zhao C; Caillier SJ; Michalak Z; Bove R; Tomic D; Santaniello A; Häring DA; Hollenbach J; Henry RG; Cree BAC; Kappos L; Leppert D; Hauser SL; Benkert P; Oksenberg JR; Kuhle J
    JAMA Neurol; 2019 Nov; 76(11):1359-1366. PubMed ID: 31403661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
    Monreal E; Fernández-Velasco JI; García-Sánchez MI; Sainz de la Maza S; Llufriu S; Álvarez-Lafuente R; Casanova B; Comabella M; Ramió-Torrentà L; Martínez-Rodríguez JE; Brieva L; Saiz A; Eichau S; Cabrera-Maqueda JM; Villarrubia N; Espiño M; Pérez-Miralles F; Montalbán X; Tintoré M; Quiroga-Varela A; Domínguez-Mozo MI; Rodríguez-Jorge F; Chico-García JL; Lourido D; Álvarez-Cermeño JC; Masjuan J; Costa-Frossard L; Villar LM
    JAMA Neurol; 2023 Apr; 80(4):397-403. PubMed ID: 36848127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
    Thebault S; Reaume M; Marrie RA; Marriott JJ; Furlan R; Laroni A; Booth RA; Uccelli A; Freedman MS
    Mult Scler Relat Disord; 2022 Mar; 59():103535. PubMed ID: 35078125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
    Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
    Monreal E; Fernández-Velasco JI; Álvarez-Lafuente R; Sainz de la Maza S; García-Sánchez MI; Llufriu S; Casanova B; Comabella M; Martínez-Yélamos S; Galimberti D; Ramió-Torrentà L; Martínez-Ginés ML; Aladro Y; Ayuso L; Martínez-Rodríguez JE; Brieva L; Villarrubia N; Eichau S; Zamora J; Rodero-Romero A; Espiño M; Blanco Y; Saiz A; Montalbán X; Tintoré M; Domínguez-Mozo MI; Cuello JP; Romero-Pinel L; Ghezzi L; Pilo de la Fuente B; Pérez-Miralles F; Quiroga-Varela A; Rubio L; Rodríguez-Jorge F; Chico-García JL; Sainz-Amo R; Masjuan J; Costa-Frossard L; Villar LM
    Brain; 2024 Aug; ():. PubMed ID: 39101570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.
    Abdelhak A; Benkert P; Schaedelin S; Boscardin WJ; Cordano C; Oechtering J; Ananth K; Granziera C; Melie-Garcia L; Montes SC; Beaudry-Richard A; Achtnichts L; Oertel FC; Lalive PH; Leppert D; Müller S; Henry RG; Pot C; Matthias A; Salmen A; Oksenberg JR; Disanto G; Zecca C; D'Souza M; Du Pasquier R; Bridel C; Gobbi C; Kappos L; Hauser SL; Cree BAC; Kuhle J; Green AJ;
    JAMA Neurol; 2023 Dec; 80(12):1317-1325. PubMed ID: 37930670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.
    Comabella M; Sastre-Garriga J; Carbonell-Mirabent P; Fissolo N; Tur C; Malhotra S; Pareto D; Aymerich FX; Río J; Rovira A; Tintoré M; Montalban X
    J Neurol Neurosurg Psychiatry; 2022 Apr; ():. PubMed ID: 35487685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
    Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
    Bjornevik K; Munger KL; Cortese M; Barro C; Healy BC; Niebuhr DW; Scher AI; Kuhle J; Ascherio A
    JAMA Neurol; 2020 Jan; 77(1):58-64. PubMed ID: 31515562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chains in progressive multiple sclerosis patients treated with repeated cycles of high-dose intravenous steroids.
    Stork L; Haupts M; Kruse N; Spill-Askeridis P; Kutllovci A; Weber MS; Brück W; Metz I
    Free Neuropathol; 2023 Jan; 4():. PubMed ID: 37859628
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.